Exploring the Potential of Antidepressants in Treating Coronary Artery Disease

BackgroundCoronary artery disease (CAD) is a leading cause of death, and depression exacerbates CAD. Antidepressants may offer therapeutic potential for CAD. MethodsWe employed Mendelian Randomization (MR), summary-based MR (SMR), colocalization, replication analysis, and single-cell RNA annotations to assess causal relationships between antidepressant targets and CAD. Safety profiles were evaluated using the Food and Drug Administrations (FDA) Adverse Event Reporting System (FAERS). ResultsFifteen proteins demonstrated significant associations with CAD. GM2A (odds ratio [OR]: 0.975, P = 4 x 10-3), PYGL, BCHE, and several others were found to reduce the risk of CAD, while PDE4A (OR: 1.183, P < 1 x 10-3) and others were associated with an increased risk. GM2A passed sensitivity analyses and exhibited strong colocalization (posterior probability of colocalization [PPH.4] > 0.8). Elevated expression of GM2A consistently showed an inverse association with CAD risk across six tissue types, with cell-type-specific patterns observed in endothelial cells and macrophages. In SMR, FOLH1 was identified as a replicable protective factor for CAD. The FAERS recorded 52,952 adverse events (AEs) related to the selected antidepressant, affecting 6,391 patients. The predominant AEs included drug withdrawal syndrome, dizziness, paresthesia, and nausea. Significant safety signals were identified for dysphoria (reporting odds ratio [ROR] 708.12) and affect lability (ROR 362.05). Additionally, unexpected events such as insomnia, anxiety, fatigue, irritability, headache, and agitation were noted. ConclusionsOur findings suggest that antidepressants may have a therapeutic role in the treatment of CAD, with GM2A identified as a promising target for therapy. While certain antidepressants can influence CAD risk, further validation is necessary to address safety concerns.